Regarding the new coronavirus oral drug "Lagebrio" distributed by the government, the Japanese corporation of the manufacturing company announced that it will start distribution through a wholesale company in the same way as general pharmaceuticals, saying that the production system for the drug is in place.
It is hoped that it will be quickly prescribed to patients who need it.
The new corona treatment drug "Lagebrio" developed by American pharmaceutical giant Merck was approved in December last year as the first oral drug for mild patients, and the government distributes it to patients at risk of becoming severe in Japan. It has been administered to more than 380,000 people so far.
Regarding this oral medicine, the company's Japanese subsidiary "MSD" announced on the 18th that it will soon begin distribution in the same way as general pharmaceuticals, saying that the production system of the medicine is in place and that it is expected to be supplied stably.
Until now, the distribution volume was limited, so the government purchased it and pharmacies and medical institutions registered it at the "registration center" to receive it, but in the future, it will be distributed to medical sites through wholesale companies. is.
Along with this, the drug price was set at about 94,000 yen when taken twice a day for 5 days, which is the prescribed dosage. It means that there is no
MSD said, ``It will be easier for pharmacies and medical institutions to secure the necessary amount of medicine, and we will be able to prescribe it to patients as soon as possible.As soon as it is ready, we will start general distribution as soon as possible.'' .